Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9

被引:7
|
作者
Hummel, MA
Tracy, TS
Hutzler, JM
Wahlstrom, JL
Zhou, YH
Rock, DA
机构
[1] Pfizer Inc, Pfizer Global Res & Dev, St Louis Labs, Pharmacokinet Dynam & Metab, St Louis, MO 63017 USA
[2] Univ Minnesota, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
关键词
CYP2C9; drug interactions; fluorescent; inhibition; cytochrome b5;
D O I
10.1177/1087057105285612
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
7-Methoxy-4-trifluoromethylcoumarin (MFC) has been used extensively in high-throughput screens for the identification of potential CYP2C9 interactions. More recently, additional probes from Invitrogen have been used. Vivid 2C9 Green is the largest of the probes and has had limited prior characterization. The new series of probes differ significantly from MFC and were examined for their ability to identify interactions with 19 CYP2C9 substrates/inhibitors. The inhibition profiles depend largely oil the physical differences between the fluorescent probe substrates. Cytochrome b5 (cytb5) was also investigated for the ability to alter the inhibition profile of a given compound. The stoichometric addition of cyt b5 caused an increase in Vmax of MFC and Vivid 2C9 Green 4.4 and 1.7 times, respectively. Furthermore, cyt b5 imposes a steric component to the active site as the inhibition profiles were significantly affected in incubations with MFC. The addition of cyt b5 had limited impact on the inhibition profiles generated with Vivid 2C9 Green. The K,, of Vivid 2C9 Green increased from 1.2 +/- 0.2 mu M to 4.8 +/- 0.3 mu M as a result of cyt b5 addition. These results illustrate that multiple substrate probes may be necessary for screening drug-drug interaction in CYP2C9 and that cyt b5 effects can impart steric restraints on the CYP2C9 active site.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 50 条
  • [21] Warfarin metabolism and anticoagulant effect:: A prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions
    Muszkat, Mordechai
    Blotnik, Simcha
    Elami, Amir
    Krasilnikov, Irena
    Caraco, Yoseph
    CLINICAL THERAPEUTICS, 2007, 29 (03) : 427 - 437
  • [22] CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: Switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant
    Hummel, MA
    Locuson, CW
    Gannett, PM
    Rock, DA
    Mosher, CM
    Rettie, AE
    Tracy, TS
    MOLECULAR PHARMACOLOGY, 2005, 68 (03) : 644 - 651
  • [23] Insights into CYP2B6-mediated drug-drug interactions
    Hedrich, William D.
    Hassan, Hazem E.
    Wang, Hongbing
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 413 - 425
  • [24] Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor
    Xiao, Jim J.
    Nowak, Dorota
    Ramlau, Rodryg
    Tomaszewska-Kiecana, Monika
    Wysocki, Piotr J.
    Isaacson, Jeff
    Beltman, Jeri
    Nash, Eileen
    Kaczanowski, Robert
    Arold, Gerhard
    Watkins, Simon
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (01): : 58 - 65
  • [25] A Fluorescent-Probe Detecting CYP2C9*3 DNA
    Li Qing-yong
    Qu Zhen-huan
    Zu Yuan-gang
    Fu Yu-jie
    SPECTROSCOPY AND SPECTRAL ANALYSIS, 2010, 30 (06) : 1520 - 1524
  • [26] A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF VADADUSTAT ON THE PHARMACOKINETICS OF CELECOXIB, A CYP2C9 SUBSTRATE IN HEALTHY VOLUNTEERS
    Chandorkar, Gurudatt A.
    Farzaneh-Far, Ramin
    Buch, Akshay
    Maroni, Bradley
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 197 - 197
  • [27] Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9
    Klein, Kerenaftali
    Gueorguieva, Ivelina
    Aarons, Leon
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (02) : 147 - 160
  • [28] Design and synthesis of a new fluorescent probe for the evaluation of potential drug-drug interactions at the CYP 3A4 level
    Chougnet, A
    Meyer, D
    Müller, M
    Ricard, D
    Stoessel, C
    Woggon, WD
    CYTOCHROMES P450, BIOCHEMISTRY, BIOPHYSICS AND DRUG METABOLISM, 2003, : 15 - 23
  • [29] CYP2C9 genotype as a predictor of drug disposition in humans
    Lee, CR
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2004, 26 (06): : 463 - 472
  • [30] Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib
    De Zwart, Loeckie
    Snoeys, Jan
    Jacobs, Frank
    Li, Lilian Y.
    Poggesi, Italo
    Verboven, Peter
    Goris, Ivo
    Scheers, Ellen
    Wynant, Inneke
    Monshouwer, Mario
    Mamidi, Rao N. V. S.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (09): : 1107 - 1118